GSK To Buy Domantis

GlaxoSmithKline PLC (NYSE: GSK) has agreed to acquire Domantis Ltd., a UK-based provider of antibody therapies, for Gbp230 million in cash. Domantis has raised around $83 million in total VC funding from firms like 3i Group, Novo Nordisk, MC Life Science Ventures, Gray Ghost, Albany Ventures, MVM, ISIS Equity Partners and Peptech Ltd.